Scholarlink

Background <p>Phospholamban (<i>PLN</i>) p.Arg14del (R14del, R14<sup>∆/+</sup>) is the most commonly identified pathogenic variant that causes cardiomyopathy in the Netherlands. Many disease characteristics are still unclear, including the phenotypic triggers, disease progression and disease-specific biomarkers. We aim to gain a&#xa0;better understanding of the R14<sup>∆/+</sup> pathophysiology by establishing a&#xa0;cohort across the R14<sup>∆/+</sup> disease spectrum.</p> Methods <p>The Disease spECifIc PatHways and modifiERs in PhosphoLambaN r14del cardiomyopathy <b>(</b>DECIPHER-PLN) cohort includes 101 participants, categorised as unaffected R14<sup>∆/+</sup> (<i>n</i> = 21), early affected R14<sup>∆/+</sup> (<i>n</i> = 42), end-stage R14<sup>∆/+</sup> (<i>n</i> = 28) and heart failure (HF) of another aetiology (<i>n</i> = 10). R14<sup>∆/+</sup> category was based on left ventricular ejection fraction, HF symptoms, electrocardiogram (ECG) and N‑terminal pro-brain natriuretic peptide concentrations. Of the 91&#xa0;included R14<sup>∆/+</sup> carriers, 46 (51%) were female, with a&#xa0;mean age of 55&#xa0;years (standard deviation: 14). Low-voltage ECG older age, arrhythmias, and conduction and repolarisation abnormalities were common in (early) affected R14<sup>∆/+</sup> carriers. Serum and plasma were collected from all participants. Induced pluripotent stem cells were generated from fibroblasts of end-stage R14<sup>∆/+</sup> patients and unaffected R14<sup>∆/+</sup> family members (<i>n</i> = 4) and differentiated into cardiomyocytes. Explanted heart tissue was obtained from R14<sup>∆/+</sup> patients undergoing cardiac surgery and patients with other HF aetiologies as control. Abnormal PLN protein localisation was confirmed in R14<sup>∆/+</sup> carriers.</p> Conclusion <p>DECIPHER-PLN comprises R14<sup>∆/+</sup> carriers across the disease and non-disease spectrum and can be used to identify disease-specific biological pathways and modifiers that play a&#xa0;role in R14<sup>∆/+</sup> cardiomyopathy. Using a&#xa0;multi-omics approach and in vitro disease modelling, we aim to identify novel biomarkers and improve our understanding of R14<sup>∆/+</sup> pathophysiology. Material is available upon request.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月6日

查看全文
  • Frederik E. Deiman,
  • Remco de Brouwer,
  • Lukas Baumhove,
  • Nils Bomer,
  • Niels Grote Beverborg,
  • Peter van der Meer

摘要

Background

Phospholamban (PLN) p.Arg14del (R14del, R14∆/+) is the most commonly identified pathogenic variant that causes cardiomyopathy in the Netherlands. Many disease characteristics are still unclear, including the phenotypic triggers, disease progression and disease-specific biomarkers. We aim to gain a better understanding of the R14∆/+ pathophysiology by establishing a cohort across the R14∆/+ disease spectrum.

Methods

The Disease spECifIc PatHways and modifiERs in PhosphoLambaN r14del cardiomyopathy (DECIPHER-PLN) cohort includes 101 participants, categorised as unaffected R14∆/+ (n = 21), early affected R14∆/+ (n = 42), end-stage R14∆/+ (n = 28) and heart failure (HF) of another aetiology (n = 10). R14∆/+ category was based on left ventricular ejection fraction, HF symptoms, electrocardiogram (ECG) and N‑terminal pro-brain natriuretic peptide concentrations. Of the 91 included R14∆/+ carriers, 46 (51%) were female, with a mean age of 55 years (standard deviation: 14). Low-voltage ECG older age, arrhythmias, and conduction and repolarisation abnormalities were common in (early) affected R14∆/+ carriers. Serum and plasma were collected from all participants. Induced pluripotent stem cells were generated from fibroblasts of end-stage R14∆/+ patients and unaffected R14∆/+ family members (n = 4) and differentiated into cardiomyocytes. Explanted heart tissue was obtained from R14∆/+ patients undergoing cardiac surgery and patients with other HF aetiologies as control. Abnormal PLN protein localisation was confirmed in R14∆/+ carriers.

Conclusion

DECIPHER-PLN comprises R14∆/+ carriers across the disease and non-disease spectrum and can be used to identify disease-specific biological pathways and modifiers that play a role in R14∆/+ cardiomyopathy. Using a multi-omics approach and in vitro disease modelling, we aim to identify novel biomarkers and improve our understanding of R14∆/+ pathophysiology. Material is available upon request.